A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
Status:
Completed
Trial end date:
2020-01-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of pirfenidone in
participants with fibrosing interstitial lung disease (ILD) who cannot be classified with
moderate or high confidence into any other category of fibrosing ILD by multidisciplinary
team (MDT) review ("unclassifiable" ILD).